Highlights eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.6 ^USD	-5.88%		-10.11%	-86.31%

May. 20	EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	CI
May. 09	EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer	May. 20	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Health Care Down on Retreat From Risk -- Health Care Roundup	Apr. 04	DJ
Top Midday Decliners	Apr. 04	MT
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer	Apr. 04	CI
Top Premarket Decliners	Mar. 26	MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 25	CI
EFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients	Dec. 08	CI
EFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer	Nov. 28	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia	23-10-24	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Debt Talks Progress Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-05-26	MT
EFFECTOR Reports 'Positive' Data Updates in Mid-Stage Breast Cancer Trial; Shares Soar After-Hours	23-05-25	MT
EFFECTOR Therapeutics, Inc. Announces Positive Interim Data Updates from Phase 2 Expansion Cohort Evaluating Zotatifin Combined with Fulfvestrant and Abemaciclib	23-05-25	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
EFFECTOR Therapeutics, Inc. to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer	23-04-11	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-08	CI
EFFECTOR Therapeutics, Inc. Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID	23-02-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Highlights

Filters